Clinical Medicine Journal
Articles Information
Clinical Medicine Journal, Vol.2, No.1, Feb. 2016, Pub. Date: Feb. 4, 2016
Comparison Between Bromocriptine and Cabergoline Drugs as a Treatment of Hyperprolactinemia Among Sudanese Infertile Amenorrhic Women
Pages: 1-5 Views: 671 Downloads: 488
Authors
[01] Hanadi Elsir AL Bashir, College of Medical Laboratory Science, Department of Clinical Chemistry, Ommuderman Islamic University, Khartoum, Sudan.
[02] Khalda Mirghani Hamza, College of Medical Laboratory Science, Department of Hematology, Sudan University of Science and Technology, Khartoum, Sudan.
Abstract
This is a retrospective study, conducted at Reproductive Health Care Centre, Khartoum. The study aimed to compare between bromocriptine and cabergoline medications for treatment of hyperprolactinema among infertile a menorrhic Sudanese Women. 105 women were selected for the study, 54 were treated with bromcriptine and 51 treated with cabergoline. The study continued for 22 weeks. Serum prolactin level was measured initially and after weeks 2, 4, 6, 8, 10, 12, 16, 18, 20, and 22. The efficacy of both treatments was assessed by normalization of serum prolactin level, menstrual cycle resumption, pregnancy achievement and side effects of both medications. The results showed that cabergoline is more effective compared to bromcriptine in terms of normalization of prolactin serum level, menstrual cycle resumption and pregnancy achievement. Both medications showed common side effects but to a lesser extent by cabergoline.
Keywords
Pregnancy, Prolactin, Infertility, Amenorrhea
References
[01] Warren MP, Biller BW, Shangold M M. A new clinical option for hormone replacement therapy in women with secondary a menorrhea: effects of cyclic administration of progesterone from the sustained – release vaginal gel Crinone (4% and 8%) on endometrial morphological features and withdrawal bleeding. Am J Obstet Gynecol 1999; 180: 42-8.
[02] Santtoro N, Filicori M, Crowely WF Jr. Hyponadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev 1986; 7: 11-23.
[03] Wang A M, Mullan Rebecca J, Lane M A et al., Treatment of hyperprolactinemia: a Systemic review. BioMed Central. Systematic Reviews 20121:3 2012.
[04] Serri O, Chik CL, Ezzat S. Diagnosis and management of hyperprolactinemia CMAJ 2003; 575-81.
[05] Kvernmo T, Hartter S, Burger E. A review of the receptor – binding and pharmacokinetic properties of dopamine agonists. Clinical Therapy 2006; 28:1065-1078.
[06] Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investing Drugs 2002; 11: 787-800.
[07] del Dotto and Bonuccelli U. Clinical pharmacokinetics of Cabergoline. Clin Pharmacok 2003; 42: 633-645.(7)
[08] Emre B, Bakiner O, Bozkirli E D et al., Successful Management of a Giant Pituitary Lactosomatroph Adenoma Only with Cabergoline. Case Reports in Endocrinology 2013; 2013. ID 134241, 4 pages.
[09] Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Cola A. Resistance to Cabergoloine as compared to Bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endoinol Metab 2001; 86: 5256-5261.
[10] AL-Husaynei AJ, Mohammed IH, AL-Jubori, M, Zena S. Comparison of the effect of Cabergoline and Bromcriptine in women with hyperprolactinemic amenorrhea. Middle East Society Journal 2008; 13: 133-138.
[11] de Santos N V, El Dib R, Boquszewski CL et al , Cabergoline versus Bromocriptine in the treatment of hyperprolactinemia : a systemic review of randomized controlled trials and meta-analysis. Pituitary 2011; 14 (3): 259-65.
[12] Motazedian S, Babakhani L, Fereshtehnejad SM and Mojtahedi K. A comparison of Bromocriptine and Cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian Journal Med Res 2010; 131: 670-674.
[13] Essais O, Bouguerra R, Hamzaoui J. Efficacy and safety of bromcriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) 2002; 63: 524-531.
[14] Kars M, Dekkers OM, Pereira AM, Romijn JA. Update in prolactinemia. Neth J Med 2010; 68: 104-112.
[15] Almalki M H, Alzahrani S, Alshahrani F et al., Managing Prolactinomas during Pregnancy. Frontiers in Endocrinology 2015; 6 (85).
[16] Sabuncu T, Arikan E, Hatem. Comparison of the effects of Cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Inter. Med. (PubMed) 2001; 40 (9): 857-61.
[17] Qari F A, FRCP, ABIN. Manifestation of hyperprolactinemia and its management by Bromcriptine and Cabergoline. JKAU: Med. Sc. 2008; 15(1): 51-62.
[18] Arduc A, Gokay F, Isiks et al., Retrospective comparison between cabergoline and bromocriptine effects in hyperprolactinemia: a single centre experience. Journal of Endocrinological Investigation 2015; 38 (4): 447-53.
[19] Berinder K, Stackenas I, Akre O, Hirschberg AL, and Hulting AL Hyperprolactinemia in 271 women: up to three decades of clinical follow – up. Clinical Endocrinol (Oxf) 2005; 63: 450-455.
[20] Cola A, Abs R, Barcena DG et al., Pregnancy outcomes following cabergoline treatment: extended results from a 12 – year observational study. Clin Endocrinol (Oxf) 2008a; 68: 66-71.
[21] Crosignani PG. Management of hyperprolactinemic infertility (Review). Middle East Fertility Journal 2012, 17 (2): 63-69.
600 ATLANTIC AVE, BOSTON,
MA 02210, USA
+001-6179630233
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - 2017 American Institute of Science except certain content provided by third parties.